Vasculitis describes a group of rare diseases that inflame blood vessels, damaging organs from the kidneys to the lungs to the skin. Treatment often starts with steroids to stop the inflammation, then shifts to steroid-sparing drugs that keep the disease quiet long-term. Most forms are chronic, requiring years of medication to prevent flares.
What's actually going on in research
Trials are testing targeted biologics that block specific immune pathways, including JAK inhibitors, IL-6 blockers, and complement inhibitors. Researchers are looking for ways to predict flares before they happen, reduce steroid exposure, and find better treatments for the hardest forms like eosinophilic granulomatosis with polyangiitis and giant cell arteritis.
Targeted immune therapies
Drugs like rituximab and mepolizumab are now standard for certain vasculitis types, and trials are testing whether JAK inhibitors and other biologics can control disease with fewer side effects. The goal is to replace steroids as the backbone of treatment.
Biomarkers for flares
Researchers are studying blood markers and imaging that might detect disease activity before symptoms appear. Early detection could allow doctors to adjust treatment before organs are damaged.
What to know before you search
Eligibility typically depends on vasculitis type, disease activity, organ involvement, and prior treatments including whether someone has tried or failed rituximab or other biologics.
What types of trials are currently open
- Treatment trials — Testing new biologics or small molecule drugs to control inflammation, often comparing them to standard steroid-based treatment.
- Maintenance trials — Testing drugs to keep vasculitis in remission after initial treatment, aiming to prevent flares while minimizing steroid use.
- Steroid-sparing trials — Studies of treatments that allow people to reduce or stop steroids, which carry serious long-term risks.
- Relapse prevention trials — Testing strategies to predict and prevent flares in people whose disease is currently controlled.
- Natural history studies — Following people with vasculitis over time to understand how different forms of the disease behave and what predicts outcomes.
Recently added Vasculitis trials
Take kidney disease medications guided by regular blood marker checks
The goal of this open-label, randomized study is to evaluate the efficacy and safety of the personalized treatment model in which Gd-IgA1 is dynamically monitored to guide medication adjustment in progressive IgAN patients treated with Nefecon or telitacicept. Researchers will compare two groups of participants: those who have Gd-IgA1 checked regularly during treatment, and those who do not. This is to find out if regular Gd-IgA1 checks can help doctors adjust medication better and get better treatment results.
Share your medical records to help evaluate a new therapy for rare vasculitis
This is a multicenter, retro-prospective observational study evaluating the effectiveness and safety of benralizumab in adult patients with eosinophilic granulomatosis with polyangiitis (EGPA) in a real-world setting. The study will include patients treated with benralizumab 30 mg every 4 weeks at EGPA referral centers participating in the European EGPA Study Group. Clinical, laboratory, lung function, treatment, relapse, and safety data will be collected from medical charts at baseline and during follow-up up to 24 months.
Find Vasculitis trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.